← Back to Search

FDG PET/CT Scan for Glioblastoma

N/A

Recruiting

Led By Johannes Czernin, MD

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with histologically proven high grade glioma

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline up to 48 hours

Awards & highlights

Study Summary

This trial will study whether FDG PET/CT can help measure early therapy response in patients with glioblastoma.

Who is the study for?

This trial is for patients with high-grade glioma, specifically glioblastoma, who are about to start therapy. They must be able to provide written consent and not have severe psychiatric illnesses. Pregnant or breastfeeding individuals cannot participate.Check my eligibility

What is being tested?

The study is testing the use of FDG PET/CT scans in detecting early responses to treatment in glioblastoma patients. It aims to see if changes in tumor glucose consumption after starting chemotherapy can indicate how well the treatment is working.See study design

What are the potential side effects?

Since this trial involves diagnostic procedures rather than drugs, side effects may include discomfort from the PET/CT scan process and exposure to radiation during imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a high-grade brain tumor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline up to 48 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline up to 48 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to 48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in glucose uptake

Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria

Side effects data

From 2011 Phase 2 trial • 55 Patients • NCT00062374

65%

Fatigue

64%

Hypocalcemia

60%

Nausea

58%

White blood cell count decrease

56%

Neutrophil count decrease

55%

Hemoglobin decrease

45%

Diarrhea

38%

Platelet count decreased

36%

Hyponatremia

31%

Hypophosphatemia

29%

Anorexia

29%

Hypokalemia

27%

Abdominal pain/cramping

22%

Hypomagnesemia

22%

Vomiting

20%

Hyperglycemia

20%

Hyperkalemia

20%

Lymphocyte count decrease

20%

Neuropathy-sensory

20%

Hypoalbuminemia

18%

Alanine aminotransferase increase

13%

Dyspnea

13%

Aspartate aminotransferase increase

11%

Creatinine

11%

Dehydration

11%

Dizziness

11%

Edema

Thrombosis

Alopecia

Hypernatremia

Weight loss

Hearing impaired

Constipation

Dyspepsia

Mood alteration/anxiety

Taste disturbance

Febrile neutropenia

Dysphagia

Pain, other

Hypoglycemia

Pharyngeal mucositis

Hemorrhage, NOS

CNS/cerebrovascular ischemia

Chest pain

Gastrointestinal disorder

Cardiovascular, other

Seizure

Hypotension

Muscle weakness

Creatinine increased

100%

80%

60%

40%

20%

Study treatment Arm

Arm I

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (FDG PET/CT)Experimental Treatment3 Interventions

Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2008

Completed Phase 2

~2240

Computed Tomography

2017

Completed Phase 2

~2720

Fludeoxyglucose F-18

2018

Completed Phase 2

~550

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

360 Previous Clinical Trials

27,662 Total Patients Enrolled

17 Trials studying Glioblastoma

476 Patients Enrolled for Glioblastoma

National Cancer Institute (NCI)NIH

13,664 Previous Clinical Trials

40,926,083 Total Patients Enrolled

322 Trials studying Glioblastoma

23,065 Patients Enrolled for Glioblastoma

National Institutes of Health (NIH)NIH

2,700 Previous Clinical Trials

7,506,826 Total Patients Enrolled

11 Trials studying Glioblastoma

570 Patients Enrolled for Glioblastoma

Media Library

Fludeoxyglucose F-18 Clinical Trial Eligibility Overview. Trial Name: NCT02902757 — N/A

Glioblastoma Research Study Groups: Treatment (FDG PET/CT)

Glioblastoma Clinical Trial 2023: Fludeoxyglucose F-18 Highlights & Side Effects. Trial Name: NCT02902757 — N/A

Fludeoxyglucose F-18 2023 Treatment Timeline for Medical Study. Trial Name: NCT02902757 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial restricted to adults of a certain age or is it open to all ages?

"The requirements for this clinical trial necessitate that participants be aged 18 to 99. There are currently 35 trials designed specifically for minors, while 415 studies are intended to recruit seniors."

Answered by AI

Is this scientific experiment currently recruiting participants?

"Affirmative. According to the information uploaded to clinicaltrials.gov, this medical study is currently accepting applicants. This trial was initially posted on August 25th 2015 and has been updated most recently on February 2nd 2022. Fifty participants are sought after from one location."

Answered by AI

Am I eligible to participate in this clinical trial?

"There is a selection criteria for this trial which necessitates that participants have glioblastoma and are between 18-99 years old. The study will include 50 individuals in total."

Answered by AI

How many individuals are collaborating in this trial?

"Correct. Clinicaltrials.gov has evidence that this clinical trial is searching for participants, with 50 candidates needed from 1 site. This study was first posted on August 25th 2015 and its information most recently updated on February 2nd 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

2015. "FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02902757.

All > Glioblastoma Long Beach > Glioblastoma Multiforme